title: [Biochemical markers of cardiac damage increased after carbetocin infusion during cesarean section].
abstract: BACKGROUND
  carbetocin, a potentially cardio toxic drug is used by intravenous bolus for uterine bleeding prevention during cesarean section. The aim was to assess the cardiac effects of carbetocin in patients undergoing cesarean sections.
  
  
  METHODS
  a pretest-postest design study was carried out on 74 women (23 ± 5.3 years, ASA I-II classification, no history of pregnant induced-hypertension) who underwent elective or emergency cesarean section. At surgical room entry (baseline), and after administration of carbetocin (infunded 100 μg along 30 minutes) during the anesthesic-surgical follow up, vital signs and EKG were registered; and CK, CK MB, and troponin I blood levels were measured. Wilcoxon's rank test was used.
  
  
  RESULTS
  significant changes were found on CK (30 vs. 58), CK MB (4.0 vs. 5.9), troponin I (0.01 vs. 0.03), blood sistolic pressure (110 vs. 100), blood diastolic pressure (70 vs. 60) and heart rate (76 vs. 90); all of them: p < 0.001. However, no patient showed heart ischemia signs during EKG monitoring.
  
  
  CONCLUSIONS
  an increase on biochemical indicators of myocardiac damage blood levels was observed after the administration of a carbetocin bolus in patients underwent cesarean section.
authors.affiliation: Departamento de Inhaloterapia, Hospital de Especialidades 1, Instituto Mexicano del Seguro Social, Mérida, Yucatán, México. gonzalo2@prodigy.net.mx
authors.forename: Gonzalo de Jesús
authors.initials: Gde J
authors.lastname: Gamboa-López
authors.forename: Patricia Berenice
authors.initials: PB
authors.lastname: Bolado-García
authors.forename: José
authors.initials: J
authors.lastname: Alvarez-Nemegyei
mesh_terms: D000293:Adolescent; D000328:Adult; D015415:Biomarkers / Q000097:blood; D002585:Cesarean Section; D005260:Female; D006331:Heart Diseases / Q000097:blood* / Q000139:chemically induced*; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D007262:Infusions, Intravenous; D007430:Intraoperative Care; D007431:Intraoperative Complications / Q000139:chemically induced* / Q000517:prevention & control; D010121:Oxytocin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011247:Pregnancy; D055815:Young Adult
chemical_list: D015415:Biomarkers; D010121:Oxytocin; C020731:carbetocin